Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Harmony Biosciences Holdings' Liabilities and Shareholders Equity rose 30.18% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 26.88%. This contributed to the annual value of $999.2 million for FY2024, which is 23.14% up from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' Liabilities and Shareholders Equity is $1.2 billion, which was up 9.04% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2025 and a low of $337.3 million during Q1 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $915.4 million, with a median of $858.4 million in 2024.
  • Data for Harmony Biosciences Holdings' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 64.53% (in 2022) over the last 5 years.
  • Over the past 5 years, Harmony Biosciences Holdings' Liabilities and Shareholders Equity (Quarterly) stood at $433.4 million in 2021, then skyrocketed by 55.47% to $673.9 million in 2022, then climbed by 20.42% to $811.4 million in 2023, then climbed by 23.14% to $999.2 million in 2024, then surged by 30.18% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.